摘要
柯萨奇B组病毒(CVB3)是导致人类急慢性心肌炎、扩张性心肌病的重要病原体之一。目前还没有疫苗或有效的药物防治病毒性心肌炎,我们观测了以水疱性口炎病毒VSV为载体的疫苗皮下免疫诱导的CVB3特异性免疫应答及保护效果,并比较了与传统蛋白疫苗之间的差异。以VSV为载体的病毒疫苗在小鼠模型中通过皮下免疫可以诱导强劲的体液免疫和T细胞免疫,但与VP1蛋白疫苗比较,除了分泌IFN-γ的T细胞外差异无统计学意义。VSV-VP1免疫组(一次免疫)的保护效果略好于VP1蛋白免疫组(三次免疫),提示VSV-VP1疫苗保护效果增加的可能原因是VSV-VP1皮下免疫诱导的特异性分泌IFN-γ的T细胞的比例增加,以上实验结果为水疱性口炎病毒作为疫苗载体应用提供了理论基础。
Coxsackievirus B3（CVB3）is an important etiological agent of acute,chronic viral myocarditis,and dilated cardiomyopathy（DCM）.There is currently no vaccine or therapeutic reagent in clinical use.In this study,we analyzed the immune responses specific to CVB3 after subcutaneous administration of a recombinant vesicular stomatitis virus（VSV）based vaccine VSV-VP1 and compared the efficiency with subunit vaccine VP1.Our data indicated that immunization with VSV-VP1 could induce strong CVB3 specific humoral and cellular immune responses,however,these were not statistically significant compared with VP1 immunization except the IFN-γsecreting T cells.The survival rate after lethal dose infection was slightly higher in the VSV-VP1 group than that receiving VP1 protein vaccine,which could be attributed to the increased IFN-γsecreting T cells.These findings provide some clues to the rational application of VSV as a viral delivery vector.
出处
《现代免疫学》
CAS
CSCD
北大核心
2015年第2期89-95,共7页
Current Immunology
基金
国家自然科学基金项目(31470848
31270977)
教育部留学回国人员科研启动基金
江苏省创新团队基金
